TY - JOUR
T1 - EAACI Biologicals Guidelines-Recommendations for severe asthma
AU - Agache, Ioana
AU - Akdis, Cezmi A
AU - Akdis, Mubeccel
AU - Canonica, Giorgio Walter
AU - Casale, Thomas
AU - Chivato, Tomas
AU - Corren, Jonathan
AU - Chu, Derek K
AU - Del Giacco, Stefano
AU - Eiwegger, Thomas
AU - Flood, Breda
AU - Firinu, Davide
AU - Gern, James E
AU - Hamelmann, Eckard
AU - Hanania, Nicola
AU - Hernández-Martín, Irene
AU - Knibb, Rebeca
AU - Mäkelä, Mika
AU - Nair, Parameswaran
AU - O'Mahony, Liam
AU - Papadopoulos, Nikolaos G
AU - Papi, Alberto
AU - Park, Hae-Sim
AU - Pérez de Llano, Luis
AU - Pfaar, Oliver
AU - Quirce, Santiago
AU - Sastre, Joaquin
AU - Shamji, Mohamed
AU - Schwarze, Jurgen
AU - Palomares, Oscar
AU - Jutel, Marek
N1 - Funding Information:
The GDG is grateful to all the methodology team from the Iberoamerican Cochrane Center (Biomedical Research Institute Sant Pau) who conducted the systematic reviews for efficacy, safety and economic evidence.
Funding Information:
IA serves as Associate Editor of Allergy. CA and MA report grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Research and Education, European Commission Horizon 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca and SciBase, and CA is also on the Sanofi/Regeneron advisory board. T Casale reports grants and/or personal fees from Genentech, Novartis, Sanofi Regeneron, GSK and Amgen. JC declares grants or personal fees from AZ, Genentech/Roche, Novartis, Optinose, Sanofi, Stallergenes and Teva. JC declares grants or personal fees from AZ, Genentech/Roche, Novartis, Optinose, Sanofi, Stallergenes and Teva. DKC is an Emerging Clinician‐Scientist Research Fellow, supported by CAAIF, CSACI and AllerGen NCE Inc SG reports personal fees from AstraZeneca, GSK and Novartis. TE has received grants or other from DBV, Innovation Fund Denmark, Regeneron, the Allergy and Anaphylaxis Program SickKids; serves as associate editor for Allergy and in the local advisory board of ALK. JG reports personal fees from Regeneron, Ena Therapeutics and MedImmune/AstraZeneca, and stock options from Meissa Vaccines Inc In addition, JG has pending patents on Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines and on Adapted Rhinovirus C. NH reports funding, honoraria or personal fees from GSK, AstraZeneca, Boehringer Ingelheim, Novartis and Sanofi Genzyme, Regeneron, Genentech, Sunovion and Mylan. RK reports grants from Asthma UK, Food Standards Agency, NIH and other from Aimmune. PN reports grants and/or personal fees from AZ, Novartis, Teva, Sanofi, Roche, Novartis, Merck and Equillium. LOM reports grants from GSK and personal fees from AHL. NGP reports personal fees from Novartis, Nutricia, HAL, Menarini/Faes Farma, Sanofi, Mylan/Meda, Biomay, AstraZeneca, GSK, MSD, Asit Biotech and Boehringer Ingelheim, and grants from Gerolymatos International SA and Capricare. AP has received grants, personal fees, nonfinancial support or other from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Teva, Mundipharma, Zambon, Novartis, Menarini, Sanofi/Regeneron, Roche, Fondazione Maugeri, Fondazione Chiesi and Edmond Pharma. LP reports grants, personal fees or nonfinancial support from Novartis, AstraZeneca, GSK, Teva, Boehringer Ingelheim, Chiesi, Sanofi, Menarini, Mundipharma, Esteve and ROVI. OP reports grants, personal fees or other from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis SA, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, Novartis, Sanofi Aventis, Med Update Europe GmbH and streamedup! GmbH. SQ reports personal fees and nonfinancial support from GSK, AZ, Sanofi, Novartis, Mundipharma, Teva and Allergy Therapeutics. JSastre declares personal fees and nonfinancial support from Novartis, GSK, AstraZeneca, Sanofi and Mundipharma. MS reports personal fees or research funding from ASIT Biotech.sa, Allergy Therapeutics, ALK, Regeneron, Merck, Immune Tolerance Network, Leti Laboratorios and Allergopharma. OP received research grants from Inmunotek SL and Novartis; received fees for giving scientific lectures from Allergy Therapeutics, Amgen, AstraZeneca, Diater, GSK, Inmunotek S.L, Novartis, Sanofi Genzyme and Stallergenes; participated in advisory boards from Novartis and Sanofi Genzyme. MJ reports personal fees from ALK‐Abello, Allergopharma, Stallergenes, Anergis, Allergy Therapeutics, Circassia, Leti, Biomay, HAL, AstraZeneca, GSK, Novartis, Teva, Vectura, UCB, Takeda, Roche, Janssen, MedImmune and Chiesi. All other authors have no conflict of interest within the scope of the submitted work.
Publisher Copyright:
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
PY - 2021/1
Y1 - 2021/1
N2 - Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
AB - Severe asthma imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity, co-morbidities, complexity in care pathways and differences between national or regional healthcare systems. Better understanding of the mechanisms has enabled a stratified approach to the management of severe asthma, supporting the use of targeted treatments with biologicals. However, there are still many issues that require further clarification. These include selection of a certain biological (as they all target overlapping disease phenotypes), the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness. The EAACI Guidelines on the use of biologicals in severe asthma follow the GRADE approach in formulating recommendations for each biological and each outcome. In addition, a management algorithm for the use of biologicals in the clinic is proposed, together with future approaches and research priorities.
KW - Asthma/diagnosis
KW - Cost-Benefit Analysis
KW - Humans
KW - Phenotype
UR - http://www.scopus.com/inward/record.url?scp=85088928605&partnerID=8YFLogxK
U2 - 10.1111/all.14425
DO - 10.1111/all.14425
M3 - Journal article
C2 - 32484954
SN - 0105-4538
VL - 76
SP - 14
EP - 44
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 1
ER -